Efficacy and Tolerability of Once-Daily Telithromycin Compared with High-Dose Amoxicillin for Treatment of Community-Acquired Pneumonia

Hagberg, Lars; Torres, Arturo Manuel Fraile; Rensburg, D. van; Leroy, Bruno; Rangaraju, Manickam; Ruuth, E.

doi:10.1007/s15010-002-2096-z

Cited by 75 publications

(52 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gastrointestinal symptoms such as diarrhea were, therefore, the most commonly reported adverse events, and were usually judged by the investigator to be mild or moderate in intensity. Few patients discontinued the study because of intolerable adverse events, which supports the favorable tolerability of this agent observed in other studies [26][27][28][29][30][31][32].…”

Section: Discussionsupporting

confidence: 80%

Efficacy and Tolerability of Once-Daily Therapy with Telithromycin for 5 or 10 Days for the Treatment of Acute Maxillary Sinusitis

Roos¹,

Brunswig-Pitschner²,

Kostřica³

et al. 2002

Chemotherapy

Self Cite

View full text Add to dashboard Cite

Background: The efficacy and tolerability of oral telithromycin 800 mg once daily for 5 vs. 10 days were assessed in patients with acute maxillary sinusitis (AMS). Methods: Adults (n = 341) with confirmed AMS diagnosed on clinical signs and symptoms and sinus X-ray showing total opacity or air-fluid level were randomized to receive oral telithromycin for 5 days (followed by placebo for 5 days; n = 170) or 10 days (n = 171). Causative pathogens were isolated by pretreatment sinus puncture (day 1). Clinical and bacteriologic outcomes, and safety and tolerability endpoints were assessed. Results: Clinical cure rates post-therapy (per-protocol; days 17–21) were comparable (91.1% in the 5-day group, n = 123; 91.0% in the 10-day group, n = 133). Bacteriologic eradication rates (per-protocol) were also similar (90.7 vs. 91.3%). Both regimens were well tolerated. Conclusions: A 5-day course of telithromycin 800 mg once daily is an effective, well-tolerated treatment for adults with AMS, comparable to a 10-day regimen.

show abstract

Section: Discussionsupporting

confidence: 80%

Efficacy and Tolerability of Once-Daily Therapy with Telithromycin for 5 or 10 Days for the Treatment of Acute Maxillary Sinusitis

Roos¹,

Brunswig-Pitschner²,

Kostřica³

et al. 2002

Chemotherapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…The results of the present pooled analysis are consistent with the overall clinical and bacteriological efficacy (91.2 and 90.4%, respectively) observed in the trials of patients with CAP treated with a once-daily oral dose of telithromycin 800 mg [14,15,16,17,18,19,20]; Aventis,unpubl. data[].…”

Section: Discussionsupporting

confidence: 89%

“…This profile is accompanied by a low potential to select for, or induce, resistance among strains of gram-positive micro-organisms [12, 13]. A number of clinical trials have demonstrated clinical and bacteriological efficacy with telithromycin 800 mg once daily in patients with CAP that was equivalent to a panel of current standard treatments [14,15,16,17]. The present paper reports a pooled analysis of these and other studies of telithromycin in CAP to determine the efficacy of telithromycin specifically in patients with CAP caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Telithromycin in Community-Acquired Pneumonia Caused by Pneumococci with Reduced Susceptibility to Penicillin and/or Erythromycin

Rensburg

Fogarty²,

Kohno³

et al. 2005

Chemotherapy

Self Cite

View full text Add to dashboard Cite

Background: The efficacy of oral telithromycin was assessed in patients with community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae with reduced susceptibility to penicillin and/or erythromycin. Methods: Patients with CAP who had received telithromycin 800 mg once daily for 5 or 7–10 days (n = 2,289) in eight phase III clinical trials, or telithromycin 800 mg once daily for 7 days (n = 50) in a phase II study were included in this pooled analysis. Patients with S. pneumoniae as the cause of infection were identified, with particular focus on those infected with strains with reduced susceptibility to penicillin (intermediate, minimal inhibitory concentration (MIC) 0.12–1.0 mg/l; resistant, MIC ≧2.0 mg/l) and/or resistance to erythromycin (MIC ≧1.0 mg/l). Per-protocol clinical and bacteriological outcomes were assessed 7–14 days post-therapy in the phase III studies, and at 7–21 days post-therapy or at the end of therapy in the phase II study. Results: Of the 327 telithromycin-treated patients with S. pneumoniae infection, 61 (19%) were infected with strains with reduced susceptibility to penicillin and/or erythromycin. Clinical cure and bacterial eradication rates in these patients were 91.8% (56/61) and 93.4% (57/61), respectively. Corresponding clinical cure and bacterial eradication rates overall for all isolates of pneumococci were 94.5% (309/327) and 96.0% (314/327), respectively. All isolates with reduced susceptibility to penicillin and/or erythromycin were susceptible to telithromycin (MIC ≤1.0 mg/l). Conclusion: These results indicate that telithromycin is an effective oral antibacterial for the treatment of CAP caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin.

show abstract

“…[60][61][62][63][64][65][66][67][68][69] AECB More than 6% of US adults have AECB. 70 Approximately 50% of exacerbations are caused by typical bacteria (ie, S pneumoniae, H influenzae, and M catarrhalis).…”

Section: Capmentioning

confidence: 99%

Telithromycin new product overview

File

2005

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Efficacy and Tolerability of Once-Daily Telithromycin Compared with High-Dose Amoxicillin for Treatment of Community-Acquired Pneumonia

Abstract: Telithromycin 800 mg once daily is a convenient, optimal-spectrum, first-line treatment for CAP in adults, at least as effective and well tolerated as high-dose amoxicillin.

Cited by 75 publications

References 29 publications

Efficacy and Tolerability of Once-Daily Therapy with Telithromycin for 5 or 10 Days for the Treatment of Acute Maxillary Sinusitis

Efficacy and Tolerability of Once-Daily Therapy with Telithromycin for 5 or 10 Days for the Treatment of Acute Maxillary Sinusitis

Efficacy of Telithromycin in Community-Acquired Pneumonia Caused by Pneumococci with Reduced Susceptibility to Penicillin and/or Erythromycin

Telithromycin new product overview

Contact Info

Product

Resources

About